Buqi-Tongluo Decoction inhibits osteoclastogenesis and alleviates bone loss in ovariectomized rats by attenuating NFATc1,MAPK,NF-κB signaling  

作　　者：Yongxian Li Jinbo Yuan Wei Deng Haishan Li Yuewei Lin Jiamin Yang Kai Chen Heng Qiu Ziyi Wang Vincent Kuek Dongping Wang Zhen Zhang Bin Mai Yang Shao PanKang Qiuli Qin Jinglan Li Huizhi Guo Yanhuai Ma Danqing Guo Guoye Mo YijingFang Renxiang Tan Chenguang Zhan Teng Liu Guoning Gu Kai Yuan Yongchao Tang DeLiang Liangliang Xu Jiake Xu Shuncong Zhang 

机构地区：[1]The First Clinical Academy,Guangzhou University of Chinese Medicine,Guangzhou 510405,China [2]The First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510407,China [3]Lingnan Medical Research Center of Guangzhou University of Chinese Medicine,Guangzhou 510405,China [4]School of Biomedical Sciences,University of Western Australia,Western Australia 6102,Australia [5]School of Public Health and Management,Guangzhou University of Chinese Medicine,Guangzhou 510405,China [6]The State Key Laboratory of Pharmaceutical Biotechnology,Institute of Functional Biomolecules,Nanjing University,Nanjing 210008,China [7]Foshan Hospital of Traditional Chinese Medicine,Foshan 528000,China [8]Curtin Medical School,Curtin University,Western Australia 6102,Australia

出　　处：《Chinese Journal of Natural Medicines》2025年第1期90-101,共12页中国天然药物(英文版)

基　　金：supported by the Natural Science Foundation of Guangdong Province,China(No.2021A1515012168);the Administration of Traditional Chinese Medicine of Guangdong Province,China(Nos.20221146 and 20241091);the Basic and Applied Basic Research Fund Project in Guangdong Province,China(No.2020A1515110948);the Basic and Applied Basic Research in Jointly Funded Projects of City Schools(Institutes)Projects,China(Nos.202201020500 and 202201020295);the Project of Guangzhou Science and Technology Department,China(No.202102021040);the Guangzhou Science and Technology Plan Project,China(No.2023B03J0379);the Chinese Society of Traditional Chinese Medicine Youth Talent Lifting Project(No.2022-QNRC2-B11);the Hospital Young and Middle-aged Key Talent Cultivation Project of The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine(2023-10)。

摘　　要：Osteoporosis is a prevalent skeletal condition characterized by reduced bone mass and strength,leading to increased fragility.Buqi-Tongluo(BQTL)decoction,a traditional Chinese medicine(TCM)prescription,has yet to be fully evaluated for its potential in treating bone diseases such as osteoporosis.To investigate the mechanism by which BQTL decoction inhibits osteoclast differentiation in vitro and validate these findings through in vivo experiments.We employed MTS assays to assess the potential proliferative or toxic effects of BQTL on bone marrow macrophages(BMMs)at various concentrations.TRAc P experiments were conducted to examine BQTL's impact on osteoclast differentiation.RT-PCR and Western blot analyses were utilized to evaluate the relative expression levels of osteoclast-specific genes and proteins under BQTL stimulation.Finally,in vivo experiments were performed using an osteoporosis model to further validate the in vitro findings.This study revealed that BQTL suppressed receptor activator of NF-κB ligand(RANKL)-induced osteoclastogenesis and osteoclast resorption activity in vitro in a dose-dependent manner without observable cytotoxicity.The inhibitory effects of BQTL on osteoclast formation and function were attributed to the downregulation of NFATc1 and c-fos activity,primarily through attenuation of the MAPK,NF-κB,and Calcineurin signaling pathways.BQTL's inhibitory capacity was further examined in vivo using an ovariectomized(OVX)rat model,demonstrating a strong protective effect against bone loss.BQTL may serve as an effective therapeutic TCM for the treatment of postmenopausal osteoporosis and the alleviation of bone loss induced by estrogen deficiency and related conditions.

关 键 词：OSTEOPOROSIS Estrogen deficiency OSTEOCLAST Buqi-Tongluo NFATc1 MAPK NF-ΚB 

分 类 号：R285.5[医药卫生—中药学]